SU9518: potently and selectively inhibits the cellular PDGF receptor kinase and PDGF receptor-induced cell proliferation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5329146 |
| CHEMBL ID | 357803 |
| SCHEMBL ID | 4410717 |
| MeSH ID | M0387206 |
| Synonym |
|---|
| 3-(5-{[(3z)-5-bromo-2-oxo-2,3-dihydro-1h-indol-3-ylidene]methyl}-2,4-dimethyl-1h-pyrrol-3-yl)propanoic acid |
| 3-substituted indolin-2-one 16b |
| bdbm4896 |
| CHEMBL357803 |
| 3-[5-[(z)-(5-bromo-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrol-3-yl]propanoic acid |
| SCHEMBL4410717 |
| 251356-32-8 |
| su9518 |
| AKOS040749575 |
SU9518 is an effective and safe inhibitor of PVR in rabbit models. It could potentially be used in humans for the treatment of this and other proliferative diseases of the retina.
| Excerpt | Reference | Relevance |
|---|---|---|
| "SU9518 is an effective and safe inhibitor of PVR in rabbit models, and could potentially be used in humans for the treatment of this and other proliferative diseases of the retina involving fibrosis and gliosis. " | ( SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Müller cell-induced rabbit models. Gao, G; Kazlauskas, A; Lei, H; Velez, G; Weingarden, AR, 2013) | 3.28 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 42.3067 | 0.0000 | 0.5369 | 10.0000 | AID1795704; AID69398; AID85139 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 17.9250 | 0.0006 | 0.8007 | 8.5000 | AID161396; AID1795704; AID85141 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 18.2483 | 0.0002 | 0.9420 | 10.0000 | AID1795704; AID73443; AID85140 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 17.6067 | 0.0000 | 0.4830 | 8.8000 | AID1795704; AID216762; AID85142 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||